natgillin/translations-raw huggingface dataset:
budesonid, fluticason til inhalation eller som næsespray, dexamethason der indtages gennem til at behandle astma, betændelsestilstande eller autoimmune lidelser (kortikosteroider) 
dexamethasone if taken by mouth or through to treat asthma or to treat inflammatory and autoimmune conditions (corticosteroids)
Der kan opstå medicinsk indikation for tidligere indstilling eller seponering af pegyleret interferonalfa og ribavirin. 
If medically indicated, earlier interruption or discontinuation of peginterferon alfa and ribavirin may be needed.
Alle patienter fik 12 ugers behandling med INCIVO i kombination med pegyleret interferon-alfa-2a og ribavirin. 
All patients received 12 weeks of treatment with INCIVO in combination with peginterferon alfa-2a and ribavirin.
INCIVO må ikke tages alene, men skal anvendes sammen med pegyleret interferon-alfa og ribavirin for at sikre, at behandlingen virker. 
INCIVO must not be taken alone and must be taken in combination with peginterferon alfa and ribavirin to be sure your treatment works.
Det er ikke nødvendigt at justere INCIVO-dosis hos stabile levertransplanterede patienter (se pkt. 
No dose adjustment of INCIVO is required in stable liver transplant patients (see sections 4.8 and 5.1).
Anæmi blev behandlet ved at reducere doseringen af ribavirin. 
Ribavirin dose reductions were used for management of anaemia.
Patienter, som havde ikkedetekterbart HCV-RNA (HCV-RNA ikke påvist) i uge 4 og 12, fik 24 ugers behandling med pegyleret interferon-alfa-2a og ribavirin, og patienter, som havde påviseligt HCV-RNA (HCV-RNA ikke påvist) i uge 4 og uge 12 fik 48 ugers behandling med pegyleret interferon-alfa-2a og ribavirin. 
Patients who had undetectable HCV RNA (target not detected) at weeks 4 and 12 received 24 weeks of peginterferon alfa-2a and ribavirin treatment, and patients who did not have undetectable HCV RNA (target not detected) at week 4 and week 12 received 48 weeks of peginterferon alfa-2a and ribavirin treatment.
Eftersom INCIVO skal anvendes i kombination med pegyleret interferon-alfa og ribarivin, gælder kontraindikationerne og advarslerne for disse lægemidler også for kombinationsbehandlingen. 
Because INCIVO must be used in combination with peginterferon alfa and ribavirin, the contraindications and warnings applicable to those medicinal products are applicable to combination therapy.
Du må ikke tage INCIVO, hvis du er gravid. 
Pregnancy and breast-feeding If you are pregnant, you must not take INCIVO.
Denne vejledning fungerer muligvis ikke tilsvarende, når der er anvendt en indledende behandling med pegyleret interferon-alfa og ribavirin (lead-in) før start på 
These guidelines may not perform similarly when a lead-in treatment with peginterferon alfa and ribavirin has been used prior to starting INCIVO therapy (see section 5.1).
- Patienter med ikke-detekterbar hepatitis C-virus-ribonukleinsyre (HCV-RNA) (HCV-RNA ikke påvist) i uge 4 og 12 skal behandles i yderligere 12 uger med pegyleret interferon-alfa og ribavirin alene, så den samlede behandlingsvarighed bliver 24 uger. 
- Patients with undetectable hepatitis C virus ribonucleic acid (HCV RNA) (target not detected) at weeks 4 and 12 receive an additional 12 weeks of peginterferon alfa and ribavirin alone for a total treatment duration of 24 weeks.
Omgående og permanent seponering af INCIVO, pegyleret interferon-alfa og ribavirin. 
Permanent and immediate discontinuation of INCIVO, peginterferon alfa, and ribavirin.
Efter 12 uger stoppede administration af INCIVO, og patienterne fortsatte behandling med pegyleret interferon-alfa-2a og ribavirin. 
At week 12, INCIVO dosing ended and patients continued on peginterferon alfa-2a and ribavirin treatment.
INCIVO må ikke gives som monoterapi, men skal ordineres i kombination med både pegyleret interferon-alfa og ribavirin. 
INCIVO must not be administered as monotherapy and must only be prescribed in combination with both peginterferon alfa and ribavirin.
Symptomer i anus og rektum 
Anorectal signs and symptoms
Forsigtighed tilrådes, og klinisk monitorering anbefales ved samtidig anvendelse af INCIVO. 
Caution is warranted and clinical monitoring is recommended when co-administered with INCIVO.
Forsigtighed tilrådes, og klinisk monitorering anbefales. 
Caution is warranted and clinical monitoring is recommended.
Patienter med ikke-detekterbart HCV-RNA (HCV-RNA ikke påvist) i uge 4 og 12 blev randomiseret i uge 20 til behandling i enten 24 uger eller 48 uger med pegyleret interferon-alfa-2a og ribavirin. 
Patients with undetectable HCV RNA ( target not detected) at weeks 4 and 12 were randomised at week 20 to receive either 24 weeks or 48 weeks of peginterferon alfa-2a and ribavirin treatment.
Du må ikke begynde at tage INCIVO igen, hvis din læge har afbrudt behandlingen. 
INCIVO must not be restarted if discontinued by your doctor.
4.4 vedrørende anbefalinger for kontrol af udslæt og seponering af behandling med INCIVO, ribavirin og pegyleret interferon-alfa. 
See section 4.4 for recommendations for monitoring of rash and discontinuation of INCIVO, ribavirin, and peginterferon alfa.
Behandlingsnaive patienter og tidligere relapsers, som ikke havde cirrose, og som opnåede hurtig virologisk respons (eRVR), fik behandling med INCIVO plus peginterferon alfa-2a og ribavirin i 12 uger efterfulgt af 12 ugers behandling med peginterferon alfa-2a og ribavirin (samlet behandlingsvarighed 24 uger). 
Treatment-naive patients or prior relapsers who were non-cirrhotic and achieved extended rapid virologic response (eRVR) received 12 weeks of treatment with INCIVO plus peginterferon alfa-2a and ribavirin followed by 12 weeks of treatment with peginterferon alfa-2a and ribavirin (total treatment duration of 24 weeks).
Da INCIVO altid skal anvendes sammen med pegyleret interferon-alfa og ribavirin, er det vigtigt, at du også læser afsnittene om dosisvejledninger i indlægssedlerne for disse lægemidler. 
Since INCIVO treatment always needs to be used together with peginterferon alfa and ribavirin, please also check the package leaflets for the dosage instructions of these medicines.
Tabel 17: Behandlingsresultater hos levertransplantatmodtagere inficeret med HCV 
Table 17: Treatment outcome in genotype 1 HCV-infected liver transplant recipients (Study HPC3006)
Forskellen i SVR-rater (95% konfidensinterval) mellem T12/PR 
The difference in SVR rates (95% confidence interval) between the T12/PR and Pbo/PR groups was 33 (26, 39).
Alle patienter fik INCIVO i 12 uger i kombination med standardbehandling med pegyleret interferon-alfa/ribavirin. 
All patients received 12 weeks of INCIVO in combination with the peginterferon alfa/ribavirin standard therapy.
Behandlingsnaive patienter og tidligere relapsers, som ikke opnåede eRVR, tidligere partial responders, tidligere null responders og alle patienter med cirrose fik behandling i 12 uger med INCIVO plus peginterferon alfa-2a og ribavirin efterfulgt af 36 ugers behandling med peginterferon alfa-2a og ribavirin (samlet behandlingsvarighed 48 uger). 
Treatment-naive patients and prior relapsers who did not achieve eRVR, prior partial responders, prior null responders, and all cirrhotic patients received 12 weeks of treatment with INCIVO plus peginterferon alfa-2a and ribavirin followed by 36 weeks of treatment with peginterferon alfa-2a and ribavirin (total treatment duration of 48 weeks).
Relaps blev defineret som havende detekterbart plasma-HCV RNA fra det planlagte tidspunkt for behandlingsafslutning og fremefter efter tidligere at have haft HCV RNA < 25 IE/ml på det planlagte tidspunkt for HCV-behandlingsafslutning og manglende opnåelse af SVR12. 
Relapse was defined as having detectable plasma HCV RNA from planned end of treatment onwards after previous HCV RNA < 25 IU/ml at planned end of HCV treatment, and not achieving SVR12.
Telaprevirs plasmakoncentration kan blive reduceret ved samtidig brug af plantelægemidlet perikon (Hypericum perforatum), og naturmedicin, der indeholder perikon, må derfor ikke kombineres med 
Plasma concentrations of telaprevir can be reduced by concomitant use of the herbal preparation St John's wort (Hypericum perforatum).
Alle behandlingsregimer omfattede 48 ugers behandling med pegyleret interferon-alfa-2a og ribavirin. 
All treatment regimens had a 48-week duration of peginterferon alfa-2a and ribavirin treatment.
Disse aktive stoffer omfatter alfuzosin, amiodaron, bepridil, quinidin, astemizol, terfenadin, cisaprid, pimozid, sekalealkaloider (dihydroergotamin, ergometrin, ergotamin, methylergometrin), lovastatin, 
These active substances include alfuzosin, amiodarone, bepridil, quinidine, astemizole, terfenadine, cisapride, pimozide, ergot derivatives (dihydroergotamine, ergonovine, ergotamine, methylergonovine), lovastatin, simvastatin, atorvastatin, sildenafil or tadalafil (only when used for treatment of pulmonary arterial hypertension), quetiapine and orally administered midazolam or triazolam (see section 4.5).
a) som udgør en forværring fra baseline og anses for bivirkninger hos HCV-inficerede patienter, der får INCIVOkombinationsbehandling, fra de poolede data fra de placebokontrollerede fase 2- og 3-studier Grad 3 
a Grade ≥ 2) that represent a worsening from baseline and are considered adverse drug reactions in HCV-infected patients treated with INCIVO combination treatment from the pooled data from the placebo-controlled
Andet omfatter patienter med detekterbart HCV RNA på det faktiske tidspunkt for behandlingsafslutning, men som ikke opfyldte definitionen af virologisk svigt under behandlingen, samt patienter med manglende HCV RNAvurdering under den planlagte opfølgning. 
Other includes patients with detectable HCV RNA at their actual end of treatment but who did not meet the definition of on-treatment virologic failure, and patients with a missing HCV RNA assessment during planned follow-up.
I placebokontrollerede fase 2- og 3-studier forekom alvorligt udslæt (primært eksematøst og kløende udslæt, der berører over 50% af legemsoverfladen) hos 4,8% af de patienter, der fik INCIVOkombinationsbehandling, sammenlignet med 0,4% af dem, der fik pegyleret interferon-alfa og ribavirin. 
In placebo-controlled Phase 2 and 3 trials, severe rash (primarily eczematous, pruritic and involving more than 50% body surface area) was reported in 4.8% of patients who received INCIVO combination treatment compared to 0.4% receiving peginterferon alfa and ribavirin.
Andet omfatter patienter med detekterbart HCV-RNA på det planlagte tidspunkt for behandlingsafslutning, men som ikke fik et viralt gennembrud, samt patienter med manglende SVR-vurdering under den planlagte opfølgning. 
Other includes patients with detectable HCV RNA at the planned end of treatment but who did not have viral breakthrough, and patients with a missing SVR assessment during planned follow-up.
Figur 1: Behandlingsvarighed for behandlingsnaive patienter og patienter med tilbagefald efter tidligere behandling (tidligere relapsers) 
Figure 1: Duration of treatment for treatment-naïve patients and prior treatment
BEHOLDERENS ETIKET (pakning med 1 beholder) 
BOTTLE LABEL (1-bottle pack)
Der kan gå flere uger, før udslættet er væk. 
The rash may take several weeks to resolve.
Langtids-effektdata 
5.3 Preclinical safety data
Er du i tvivl, så spørg lægen eller på apoteket. 
If you need help, ask your doctor or pharmacist.
Samtidig brug af rifampicin og telaprevir er kontraindiceret. 
Co-administration of rifampicin with telaprevir is contraindicated.
Sildenalfil eller vardenafil anbefales ikke anvendt sammen med telaprevir. 
It is not recommended to co-administer sildenafil or vardenafil and telaprevir.
Anvendelse af pegyleret interferon-alfa-2a eller -2b To typer pegyleret interferon-alfa (2a og 2b) blev undersøgt i det åbne, randomiserede fase 2a-studie C208 hos behandlingsnaive patienter. 
Use of peginterferon alfa 2a or 2b Two types of peginterferon alfa (2a and 2b) were studied in the Phase 2a open label, randomised
- For alle patienter med cirrose, uanset om de har ikke-detekterbart HCV-RNA (HCV-RNA ikke påvist) i uge 4 eller 12, anbefales supplerende behandling i 36 uger med pegyleret interferon-alfa og ribavirin alene, så den samlede behandlingsvarighed bliver 48 uger (se 
- For all patients with cirrhosis irrespective of undetectable HCV RNA (target not detected) at weeks 4 or 12, an additional 36 weeks of peginterferon alfa and ribavirin alone for a total treatment duration of 48 weeks is recommended (see section 5.1).
Samtidig anvendelse af INCIVO og lægemidler, der hæmmer CYP3A og/eller P-gp, kan øge 
Co-administration of INCIVO and medicinal products that inhibit CYP3A and/or P-gp may increase telaprevir plasma concentrations.
bosentan medfører induktion af CYP3A, telaprevis hæmmer CYP3A og organisk aniontransportpolypeptider (OATP) 
CYP3A and organic anion transporter polypeptides (OATPs) by telaprevir
Se også indlægssedlen for pegyleret interferon-alfa og ribavirin. 
See also the package leaflets for peginterferon alfa and ribavirin.
I det kliniske fase 3-studie C211 var der ingen forskel mellem den type varianter, der opstod hos patienter, som fik telaprevir 1.125 mg to gange dagligt, og typen hos patienter, som fik telaprevir 750 mg hver 8. time. 
In the C211 Phase 3 clinical trial, there was no difference in the type of emerging variants between patients receiving telaprevir 1,125 mg twice daily (b.i.d.)
Patienterne i disse studier, 108, 111 og C216, havde kompenseret leversygdom, påviseligt HCV-RNA, og lever-histopatologi svarende til kronisk hepatitis C. Med mindre andet angives, blev INCIVO givet i en dosis på 750 mg hver 8. time. 
Patients in these studies, 108, 111 and C216, had compensated liver disease, detectable HCV RNA, and liver histopathology consistent with chronic hepatitis C. Unless otherwise indicated, INCIVO was administered at a dosage of 750 mg every 8 hours (q8h); the peginterferon alfa-2a dose was 180 µg/week, and the ribavirin dose was 1,000 mg/day (patients weighing < 75 kg) or 1,200 mg/day (patients weighing ≥ 75 kg).
Relaps blev defineret som havende HCV RNA ≥ 25 IE/ml i opfølgningsperioden efter tidligere at have haft HCV RNA < 25 IE/ml på det planlagte tidspunkt for behandlingsafslutning og manglende opnåelse af SVR12. 
Relapse was defined as having HCV RNA ≥ 25 IU/ml during the follow-up period after previous HCV RNA < 25 IU/ml at planned end of treatment and not achieving SVR12.
Alle patienter fik INCIVO plus pegyleret interferon alfa-2a og ribavirin i 12 uger, efterfulgt af pegyleret interferon alfa-2a og ribavirin i 36 uger (samlet behandlingsvarighed 48 uger). 
All patients received 12 weeks of treatment with INCIVO plus peginterferon alfa-2a and ribavirin followed by 36 weeks of treatment with peginterferon alfa-2a and ribavirin (total treatment duration of 48 weeks).
In vitro fandtes ingen relevant hæmning af CYP1A2-, CYP2A6-, CYP2B6-, CYP2C8-, CYP2C9-, 
No relevant inhibition by telaprevir of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP2E1 isozymes was observed in vitro.
HCV-RNA > 1.000 IE/ml i uge 12 af behandlingen Behandling med INCIVO gennemført 
HCV RNA > 1,000 IU/ml at week 12 of treatment
Tabel 1: Vejledning i seponering af behandling med INCIVO, pegyleret interferon-alfa og ribavirin 
Table 1: Guidelines for discontinuation of INCIVO, Peginterferon Alfa, and Ribavirin treatment
- Lægen har ordineret INCIVO til dig personligt. 
- This medicine has been prescribed for you only.
Andet omfatter patienter med detekterbart HCV RNA på det faktiske tidspunkt for behandlingsafslutning, men som ikke fik et viralt gennembrud, samt patienter med manglende HCV RNA-vurdering under den planlagte opfølgning. 
Other includes patients with detectable HCV RNA at their actual end of treatment but who did not have viral breakthrough, and patients with a missing HCV RNA assessment during planned follow-up.
Pegyleret interferon-alfa-2a/pegyleret interferon-alfa-2b og ribavirin blev anvendt som angivet i de 
Peginterferon alfa-2a/peginterferon alfa-2b and ribavirin were used according to their relevant Summary of Product Characteristics.
I T12/PR48-gruppen havde 3 forsøgspersoner (8%) brofibrose ved baseline, og 2 forsøgspersoner (5%) havde cirrose. 
At baseline, 3 (8%) patients had bridging fibrosis and 2 (5%) patients had cirrhosis in the T12/PR48 arm.
Telaprevirs aktivitet mod hepatitis C 
In vitro studies Activity of telaprevir against HCV
Behandling med INCIVO skal indledes i kombination med pegyleret interferon alfa og ribavirin i 12 uger efterfulgt af pegyleret interferon alfa og ribavirin alene i yderligere 36 uger, dvs. en samlet behandlingsvarighed på 48 uger. 
Treatment with INCIVO must be initiated in combination with peginterferon alfa and ribavirin and administered for 12 weeks with an additional 36 weeks of peginterferon alfa and ribavirin alone for a total treatment duration of 48 weeks.
- INCIVO 750 mg hver 8. time sammen med pegyleret interferon-alfa-2b 1,5 g/kg/uge og 
- INCIVO 750 mg every 8 hours with peginterferon alfa-2b 1.5 g/kg/week and ribavirin
Studie HPC3006 var et åbent fase 3b-studie, der omfattede behandlingsnaive og behandlingserfarne patienter med kronisk HCV-genotype 1-infektion, som var førstegangs-levertransplantatmodtagere i stabil behandling med de immunsupprimerende midler tacrolimus eller ciclosporin. 
Study HPC3006 was an open-label, Phase 3b study in treatment- naïve and treatment-experienced chronic genotype 1 HCV- infected patients who were first time liver transplant recipients and were on a stable regimen of the immunosuppressants tacrolimus or cyclosporine A. No patients had cirrhosis of the liver graft.
Læs indlægssedlen for pegyleret interferon-alfa og ribavirin for at få yderligere oplysninger om dette. 
You must read the package leaflets for peginterferon alfa and ribavirin for additional information.
Darunavir/ritonavir anbefales ikke anvendt sammen med telaprevir (se pkt. 
It is not recommended to co-administer darunavir/ritonavir and telaprevir (see section 4.4).
Plasmakoncentrationen af HCV-RNA 
Plasma HCV RNA values were measured using the COBAS
Tabel 17 viser de samlede responsrater hos behandlingsnaive og behandlingserfarne levertransplantatmodtagere med kronisk HCV-genotype 1-infektion samt efter undergruppe 
Table 17 shows the overall response rates in treatment- naïve and treatment-experienced chronic genotype 1 HCV- infected liver transplant recipients and by subgroup (patients receiving tacrolimus or cyclosporine A).
Samtidig anvendelse af domperidon og INCIVO bør undgås (se pkt. 
Co-administration of domperidone with INCIVO should be avoided (see section 4.4).
Det er ikke nødvendigt at ændre buprenorphindosis ved samtidig anvendelse af telaprevir. 
No adjustment of the buprenorphine dose is required when co-administered with telaprevir.
Virologisk svigt i løbet af behandlingen omfatter patienter, som mødte en virologisk stopregel fastlagt i protokollen 
On-treatment-virologic failure includes patients who met a protocol-defined virologic stopping rule and/or had viral
- INCIVO 1.125 mg hver 12. time sammen med pegyleret interferon-alfa-2b 1,5 g/kg/uge og 
- INCIVO 1,125 mg every 12 hours with peginterferon alfa-2b 1.5 g/kg/week and ribavirin
etravirin* 
phenytoin*
- INCIVO 1.125 mg hver 12. time sammen med pegyleret interferon-alfa-2a 180 g/uge og 
- INCIVO 1,125 mg every 12 hours with peginterferon alfa-2a 180 g/week and ribavirin
Baseret på en populationsfarmakokinetisk model af eksponeringen for telaprevir ved steady state var ratioerne af middelværdierne (fundet ved mindste kvadraters metode; 90% CI) af 1.125 mg to gange dagligt versus 750 mg hver 8. time 1,08 (1,02; 1,13) for AUC24,ss, 0,878 (0,827; 0,930) for Ctrough,ss, og 1,18 
versus 750 mg every 8 hours (q8h) were 1.08 (1.02; 1.13) for AUC24,ss, 0.878 (0.827; 0.930) for Ctrough,ss, and 1.18 (1.12;1.24) for Cmax,ss.
Der er ilagt tørremiddel (en eller to 
Desiccant (one pouch or two
Almindelige bivirkninger (forekommer hos færre end 1 ud af 10 behandlede) - svampeinfektion i munden - lavt antal blodplader, fald i lymfocytter (en type hvide blodlegemer), nedsat aktivitet af skjoldbruskkirtlen, forhøjet urinsyre i blodet, nedsat mængde kalium i blodet, forhøjet bilirubin i blodet 
- low blood platelet count, decrease in lymphocytes (a type of white blood cell), decrease in thyroid gland activity, increase in uric acid in your blood, decrease in potassium in your blood,
Samtidig anvendelse af INCIVO og domperidon bør undgås (se pkt. 
INCIVO co-administration with domperidone should be avoided (see section 4.5).
↑ triazolam 
↑ alfentanil ↑ fentanyl
21,6% havde IL28Bgenotype CC, 54,1% havde IL28B-genotype CT, og 24,3% havde IL28B-genotype TT. 28,4% (n = 21) var HCV-behandlingsnaive, og 71,6% (n = 53) var behandlingserfarne [14,9% (n = 11) var tidligere relapsers, mens 40,5% (n = 30) var tidligere non-responders, og 16,2% (n = 12) kunne ikke klassificeres]. 
RNA levels ≥ 800,000 IU/ml; 10.8% had bridging fibrosis; none had cirrhosis; 38.9% had HCV genotype 1a; 58.3% had HCV genotype 1b; 2.8% had HCV genotype 1d; 21.6% had IL28B genotype CC; 54.1% had IL28B genotype CT; 24.3% had IL28B genotype TT; 28.4% (n = 21) were HCV treatment- naïve; 71.6% (n = 53) were treatment-experienced [14.9% (n = 11) were prior relapsers; 40.5% (n = 30) were prior non-responders; 16.2% (n = 12) could not be classified]; median time since liver transplantation was 2.5 years (range: 0.6 to 9.5 years); 67.6% (n = 50) received tacrolimus; 32.4% (n = 24) received cyclosporine A.
til at behandle psykiske lidelser (antipsykotika) 
to treat fungal infections (antifungals)
Gå til kontrol hos din læge, og følg behandlingen i den anbefalede periode. 
Please check with your doctor and follow
Den potentielle kliniske betydning af 
The potential clinical significance of these findings is uncertain.
73,8% af patienterne (59 ud af 80) i den poolede pegyleret interferon-alfa-2a-gruppe opfyldte kriterierne (ikke-detekterbart HCV-RNA (HCV-RNA ikke påvist) fra uge 4 t.o.m. 
73.8% (59/80) of patients in the pooled peginterferon alfa-2a group met the criteria (undetectable HCV RNA (target not detected) at week 4 through week 20) for the shortened 24 week peginterferon/ribavirin treatment duration versus 61.7% (50/81) of patients in the pooled
Naive patienter, der fik enten pegyleret interferon-alfa-2a/ribavirin (n = 80) eller pegyleret interferon-alfa 
Naïve patients treated with either peginterferon alfa-2a/ribavirin (n = 80) or peginterferon alfa-2b/ribavirin (n = 81) in combination with INCIVO, in an open label study, had comparable SVR rates.
Eksempler på disse blodprøver: blodbillede, skjoldbruskkirtelhormoner (dannes i kirtel i halsen og regulerer stofskiftet), lever- og 
Examples are: blood count levels, thyroid (a gland in your neck that controls your metabolism) levels, liver and kidney
T12/PR48: INCIVO i 12 uger efterfulgt af placebo i 4 uger i kombination med pegyleret interferon-alfa-2a og ribavirin i 
T12/PR48: INCIVO for 12 weeks followed by placebo for 4 weeks, in combination with peginterferon alfa-2a and
Patienter, der tager INCIVO to gange dagligt, skal informeres om, at hvis de glemmer at tage en dosis INCIVO, og det opdages inden for 6 timer efter det sædvanlige tidspunkt, skal den foreskrevne dosis INCIVO tages hurtigst muligt sammen med føde. 
), in case a dose of INCIVO is missed within 6 hours of the time it is usually taken, patients should be instructed to take the prescribed dose of INCIVO with food as soon as possible.
Salmeterol anbefales ikke anvendt sammen med telaprevir. 
Concurrent administration of salmeterol and telaprevir is not recommended.
Janssen-Cilag SpA Via M.Buonarroti, 23 
Manufacturer Janssen-Cilag SpA, Via C. Janssen,
In vitro fandtes der ingen relevant telaprevir-relateret hæmning af den organiske kation-transportør 
No relevant inhibition by telaprevir of the organic cation transporter (OCT) OCT2 was observed in vitro.
For en oversigt over kontraindikationerne for pegyleret interferon-alfa og ribavirin henvises til produktresuméerne for disse, eftersom INCIVO skal anvendes i kombination med pegyleret 
Refer to the Summary of Product Characteristics for peginterferon alfa and ribavirin for a list of their contraindications since INCIVO must be used in combination with peginterferon alfa and ribavirin.